162. 類天疱瘡（後天性表皮水疱症を含む。） Pemphigoid Clinical trials / Disease details

臨床試験数 : 90 / 薬物数 : 122 - (DrugBank : 47) / 標的遺伝子数 : 34 - 標的パスウェイ数 : 144

10 trials found

diseases per page:

Showing 1 to 10 of 10 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04128176 (ClinicalTrials.gov)	May 25, 2023	12/10/2019	Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid	An Open-Label Study to Evaluate the Efficacy and Safety of RituximabCombined With Omalizumab in Pati ...	Bullous Pemphigoid	Drug: Rituximab combined with Omalizumab	University of California, Davis	NULL	Not yet recruiting	18 Years	90 Years	All	15	Phase 3	United States
2	NCT03295383 (ClinicalTrials.gov)	July 11, 2019	22/9/2017	Randomized Clinical Trial Comparing the Safety and Efficacy of RituximabVersus Oral Cyclophosphamide ...	Randomized Double Blind Double Dummy Control Trial Comparing the Safety and Efficacy of RituximabVer ...	Severe Forms of Mucous Membrane Pemphigoid	Drug: Rituximab 1g IV;Drug: Cyclophosphamide 50Mg Oral Tablet;Drug: Placebo of Rituximab;Drug: Placebo ...	University Hospital, Rouen	NULL	Recruiting	18 Years	80 Years	All	130	Phase 3	France
3	EUCTR2018-001417-32-FR (EUCTR)	13/07/2018	11/06/2018	Long-term Follow-up of patients participants with pemphigus From Study RITUXIMAB3	Long-term Follow-up of patients participants with pemphigus From Study RITUXIMAB3. Immunological, cl ...	Patients with Bullous pemphigoid included in RITUXIMAB3 study MedDRA version: 20.0;Level: LLT;Classi ...	Trade Name: MABTHERA INN or Proposed INN: RITUXIMAB Trade Name: Prednisone Product Name: CORTANCYL 20 mg ...	CHU-Hôpitaux de Rouen	NULL	Not Recruiting			Female: yes Male: yes	77	Phase 3	France
4	JPRN-UMIN000015451	2014/11/13	25/10/2014	Exploratory research on effectiveness and safety of Rituximabtreatment including maintenance adminis ...	Exploratory research on effectiveness and safety of Rituximabtreatment including maintenance adminis ...	Pemphigus, Pemphigoid	Rituximab375mg/sqm, q1w, 4 doses. Maintenance administration of rituximabis possible if PDA or BPDAI ...	Department of Dermatology,Keio University School of Medicine	Hokkaido University, Kurume University, Okayama University, Kawasaki Medical School	Complete: follow-up complete	20years-old	80years-old	Male and Female	20	Phase 1,2	Japan
5	JPRN-jRCTs031180220	01/05/2014	15/03/2019	Rituximab treatment of blistering disease	Treatment of refractory autoimmuno blistering disease with rituximab	Pemphigus vulgaris, paraneoplastic pemphigus, bullous pemphigoid	Infusion of rituximab(1000mg) intravenously. Approximately two weeks after the first dose, a second ...	Kanaoka Miwa	Michiko Aihara	Complete	>= 20age old	< 80age old	Both	10	N/A	Japan
6	JPRN-UMIN000004428	2010/11/01	01/11/2010	Exploratory research on effectiveness and safety of Rituximabtreatment for steroid intractable pemph ...	Exploratory research on effectiveness and safety of Rituximabtreatment for steroid intractable pemph ...	pemphigus, bullous pemphigoid, epidermolysis bullosa acquisita	Rituximab	Research group of rare intractable dermatologial disorder	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	20	Phase 2	Japan
7	EUCTR2008-005266-31-FR (EUCTR)	06/02/2009	13/03/2009	COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB(MABTHERA®) ASSOCIE A U ...	COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB(MABTHERA®) ASSOCIE A U ...	Pemphogoide bulleuse MedDRA version: 9.1;Level: LLT;Classification code 10006567;Term: Bullous pemph ...	Trade Name: mabthéra Product Name: mathéra Trade Name: Prednisone Product Name: CORTANCYL 20 mg	CHU-Hôpitaux de Rouen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			France
8	NCT00525616 (ClinicalTrials.gov)	December 2008	20/7/2007	Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid	Assessment of Rituximab Efficiency and Tolerance in Treatment of Bullous Pemphigoid.	Bullous Pemphigoid	Drug: Mabthera	University Hospital, Rouen	NULL	Completed	18 Years	80 Years	Both	18	Phase 3	France
9	NCT00584935 (ClinicalTrials.gov)	January 2006	26/12/2007	Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid	Phase I/II Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid	Ocular Cicatricial Pemphigoid	Drug: Rituximab	University of Alabama at Birmingham	Genentech, Inc.;Biogen	Completed	19 Years	N/A	All	3	Phase 1/Phase 2	United States
10	NCT00286325 (ClinicalTrials.gov)	March 2005	1/2/2006	Rituximab in the Treatment of Patients With Bullous Pemphigoid	Rituximab in the Treatment of Patients With Bullous Pemphigoid	Bullous Pemphigoid	Drug: Rituximab	Duke University	Genentech, Inc.	Completed	18 Years	N/A	All	8	Phase 1/Phase 2	United States

First Previous1Next Last